Bailard, Inc. reports 11.44% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

US ˙ NasdaqGS ˙ US92532F1003

Security	VRTX / Vertex Pharmaceuticals Incorporated
Institution	Bailard, Inc.
Latest Disclosed Ownership	37,862 shares
Latest Disclosed Value	$ 16,907,047

On May 11, 2026 - Bailard, Inc. filed a 13F-HR form disclosing ownership of 37,862 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $16,906,897 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 4, 2026 disclosing 33,975 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 11.44% during the quarter. The current value of the position is $16,217,809 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-11	2026-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	37,862	3,887	11.44	16,907	9.76	0.3887
2026-02-04	2025-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	33,975	-664	-1.92	15,403	13.54	0.3410
2025-10-30	2025-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	34,639	-3,508	-9.20	13,566	-20.12	0.2948
2025-08-08	2025-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	38,147	200	0.53	16,983	-7.69	0.3959
2025-05-02	2025-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	37,947	532	1.42	18,398	22.10	0.4749
2025-02-05	2024-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	37,415	-1,102	-2.86	15,067	-15.89	0.3851
2024-10-30	2024-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	38,517	37	0.10	17,913	-0.68	0.4663
2024-07-25	2024-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	38,480	-260	-0.67	18,036	11.38	0.4969
2024-05-08	2024-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	38,740	410	1.07	16,194	3.83	0.4470
2024-02-02	2023-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	38,330	908	2.43	15,596	19.85	0.4620
2023-10-24	2023-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	37,422	1,047	2.88	13,013	1.66	0.4310
2023-07-20	2023-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	36,375	372	1.03	12,801	12.84	0.4477
2023-05-08	2023-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	36,003	23,165	180.44	11,343	205.99	0.4064
2023-02-02	2022-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	12,838	10,201	386.84	3,707	385.21	0.1412
2022-10-18	2022-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,637	2,637		764		0.0316
2021-08-13	2021-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	0	-1,591	-100.00	0	-100.00
2021-05-13	2021-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	1,591	-600	-27.38	342	-33.98	0.0127
2021-02-03	2020-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,191	59	2.77	518	-10.69	0.0236
2020-11-10	2020-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,132	-70	-3.18	580	-9.23	0.0300
2020-08-12	2020-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,202	0	0.00	639	21.95	0.0357
2020-04-16	2020-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,202	2	0.09	524	8.71	0.0373
2020-01-31	2019-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	482	29.22	0.0272
2019-10-18	2019-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	373	-7.44	0.0226
2019-07-26	2019-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	403	-0.49	0.0246
2019-04-24	2019-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	405	10.96	0.0251
2019-02-05	2018-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	365	-13.92	0.0247
2018-11-13	2018-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	424	13.37	0.0248
2018-08-08	2018-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	374	4.18	0.0223
2018-05-07	2018-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	0	0.00	359	8.79	0.0229
2018-02-08	2017-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,200	2,200		330		0.0208
2018-01-29	2016-03-31	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	0	-3,500	-100.00	0	-100.00
2018-01-29	2015-12-31	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	3,500	3,500		440		0.1947
2016-02-10	2015-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	3,500	3,500		440		0.1894

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.